Quantitative analysis of matrix metalloproteinase-2 mRNA expression in central and peripheral regions of gliomas

Brain Tumor Pathology

Volumn 28, Issue 2, 2011, Pages 137-144

  Brell, Marta ^a   Ibáñez, Javier ^a   Felpete, Ana ^a   Burguera, Bartolome ^a   Frontera, Marga ^a   Couce, Marta E ^a  

^a HUSD   (Spain)

Author keywords

Glioma; Heterogeneity; Invasiveness; Metalloproteinases; MMP 2; RT PCR

Indexed keywords

ANTINEOPLASTIC AGENT; GELATINASE A; KI 67 ANTIGEN; MESSENGER RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CELL DENSITY; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME LOCALIZATION; FEMALE; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OVERALL SURVIVAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; EXTRACELLULAR MATRIX; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 80052701962     PISSN: 14337398     EISSN: 1861387X     Source Type: Journal    
DOI: 10.1007/s10014-011-0021-9     Document Type: Article

References (43)

1. Bellail AC, Hunter SB, Brat DJ et al (2004) Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol 36:1046-1069 (Pubitemid 38501557)
2. Gabelloni P, Da PE, Bendinelli S et al (2010) Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma. Neuroscience 168:514-522
3. Jaalinoja J, Herva R, Korpela M et al (2000) Matrix metallo-proteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms. J Neurooncol 46:81-90 (Pubitemid 30352615)
4. Van MT, Dumur C, Hafez N et al (2006) Microarray analysis of MRI-defined tissue samples in glioblastoma reveals differences in regional expression of therapeutic targets. Diagn Mol Pathol 15:195-205 (Pubitemid 44813658)
5. Hoelzinger DB, Mariani L, Weis J et al (2005) Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia 7:7-16 (Pubitemid 40209466)
6. Bello L, Lucini V, Carrabba G et al (2001) Simultaneous inhibition of glioma angiogenesis, cell proliferation, and invasion by a naturally occurring fragment of human metalloproteinase-2. Cancer Res 61:8730-8736 (Pubitemid 34013884)
7. Park CK, Jung JH, Park SH et al (2009) Multifarious proteomic signatures and regional heterogeneity in glioblastomas. J Neu-rooncol 94:31-39
8. D'Abaco GM, Kaye AH (2007) Integrins: molecular determinants of glioma invasion. J Clin Neurosci 14:1041-1048 (Pubitemid 47588943)
9. Deryugina EI, Bourdon MA, Luo GX et al (1997) Matrix metalloproteinase-2 activation modulates glioma cell migration. J Cell Sci 110:2473-2482 (Pubitemid 127699161)
10. Nisato RE, Hosseini G, Sirrenberg C et al (2005) Dissecting the role of matrix metalloproteinases (MMP) and integrin alpha(v)-beta3 in angiogenesis in vitro: absence of hemopexin C domain bioactivity, but membrane-Type 1-MMP and alpha(v)beta3 are critical. Cancer Res 65:9377-9387 (Pubitemid 41508006)
11. Brooks PC, Stromblad S, Sanders LC et al (1996) Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 85:683-693 (Pubitemid 26181048)
12. Ozen O, Krebs B, Hemmerlein B et al (2004) Expression of matrix metalloproteinases and their inhibitors in medulloblasto-mas and their prognostic relevance. Clin Cancer Res 10:4746-4753 (Pubitemid 38955526)
13. Baumann F, Leukel P, Doerfelt A et al (2009) Lactate promotes glioma migration by TGF-beta2-dependent regulation of matrix metalloproteinase-2. Neuro Oncol 11:368-380
14. Bello L, Francolini M, Marthyn P et al (2001) Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neuro-surgery 49:380-389
15. Du R, Petritsch C, Lu K et al (2008) Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM. Neuro Oncol 10:254-264
16. Kong L, Li Q, Wang L et al (2007) The value and correlation between PRL-3 expression and matrix metalloproteinase activity and expression in human gliomas. Neuropathology 27:516-521 (Pubitemid 350045676)
17. Komatsu K, Nakanishi Y, Nemoto N et al (2004) Expression and quantitative analysis of matrix metalloproteinase-2 and -9 in human gliomas. Brain Tumor Pathol 21:105-112 (Pubitemid 40187984)
18. Santandreu FM, Brell M, Gene AH et al (2008) Differences in mitochondrial function and antioxidant systems between regions of human glioma. Cell Physiol Biochem 22:757-768
19. Tate MC, Aghi MK (2009) Biology of angiogenesis and invasion in glioma. Neurotherapeutics 6:447-457
20. Raithatha SA, Muzik H, Muzik H et al (2000) Localization of gelatinase-A and gelatinase-B mRNA and protein in human gli-omas. Neuro Oncol 2:145-150
21. Wang M, Wang T, Liu S et al (2003) The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades. Brain Tumor Pathol 20:65-72 (Pubitemid 38146273)
22. Kleihues P, Louis DN, Wiestler OD et al (2007) WHO grading of tumors of the central nervous system. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) The WHO Classification of Tumors of the Central Nervous System, 4th edn. International Agency for Research on Cancer (IARC), Lyon, pp 10-11
23. Going JJ (1994) Efficiently estimated histologic cell counts. Hum Pathol 25:333-336 (Pubitemid 24151116)
24. Larionov A, Krause A, Miller W (2005) A standard curve based method for relative real time PCR data processing. BMC Bioin-form 21:62
25. Tchirkov A, Rolhion C, Kemeny JL et al (2003) Clinical implications of quantitative real-time RT-PCR analysis of hTERT gene expression in human gliomas. Br J Cancer 88:516-520 (Pubitemid 36363360)
26. Valente V, Teixeira SA, Neder L et al (2009) Selection of suitable housekeeping genes for expression analysis in glioblastoma using quantitative RT-PCR. BMC Mol Biol 10:17
27. Pluderi M, Lucini V, Caronzolo D et al (2003) Long-term inhibition of glioma growth by systemic administration of human PEX. J Neurosurg Sci 47:69-78 (Pubitemid 37504948)
28. Park MH, Ahn BH, Hong YK et al (2009) Overexpression of phospholipase D enhances matrix metalloproteinase-2 expression and glioma cell invasion via protein kinase C and protein kinase A/NF-kappaB/Sp1-mediated signaling pathways. Carcinogenesis 30:356-365
29. Zhou YH, Hess KR, Liu L et al (2005) Modeling prognosis for patients with malignant astrocytic gliomas: quantifying the expression of multiple genetic markers and clinical variables. Neuro Oncol 7:485-494 (Pubitemid 41555620)
30. Yano H, Hara A, Murase S et al (2001) Expression of hepatocyte growth factor and matrix metalloproteinase-2 in human glioma. Brain Tumor Pathol 18:7-12
31. Walker C, du Plessis DG, Joyce KA et al (2003) Phenotype versus genotype in gliomas displaying inter- or intratumoral histological heterogeneity. Clin Cancer Res 9:4841-4851 (Pubitemid 37323288)
32. VanMeter TE, Rooprai HK, Kibble MM et al (2001) The role of matrix metalloproteinase genes in glioma invasion: Co-dependent and interactigve proteolysis. J Neurooncol 53:213-235 (Pubitemid 33034693)
33. Guo P, Imanishi Y, Cackowski FC et al (2005) Up-regulation of angiopoietin-2, matrix metalloprotease-2, membrane type 1 metalloprotease, and laminin 5 gamma 2 correlates with the invasiveness of human glioma. Am J Pathol 166:877-890 (Pubitemid 40315644)
34. Takano S, Tsuboi K, Matsumura A et al (2001) Localization of gelatinase activities in glioma tissues by film in situ zymography. Brain Tumor Pathol 18:145-150
35. Trog D, Yeghiazaryan K, Fountoulakis M et al (2006) Pro-invasive gene regulating effect of irradiation and combined temozolomide-radiation treatment on surviving human malignant glioma cells. Eur J Pharmacol 542:8-15 (Pubitemid 44066368)
36. Kunishio K, Okada M, Matsumoto Y et al (2003) Matrix metalloproteinase-2 and -9 expression in astrocytic tumors. Brain Tumor Pathol 20:39-45 (Pubitemid 38146269)
37. Pagenstecher A, Wussler EM, Opdenakker G et al (2001) Distinct expression patterns and levels of enzymatic activity of matrix metalloproteinases and their inhibitors in primary brain tumors. J Neuropathol Exp Neurol 60:598-612 (Pubitemid 32523624)
38. Aaberg-Jessen C, Christensen K, Offenberg H et al (2009) Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival. J Neurooncol 95:117-128
39. Silveira Correa TC, Massaro RR, Brohem CA et al (2010) RECK-mediated inhibition of glioma migration and invasion. J Cell Biochem 110:52-61
40. Fillmore HL, VanMeter TE, Broaddus WC (2001) Membranetype matrix metalloproteinases (MT-MMPs): expression and function during glioma invasion. J Neurooncol 53:187-202 (Pubitemid 33034691)
41. Figueira RC, Gomes LR, Neto JS et al (2009) Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer 9:20
42. Noda M, Oh J, Takahashi R et al (2003) RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling. Cancer Metastasis Rev 22:167-175 (Pubitemid 36561056)
43. Dunn J, Baborie A, Alam F et al (2009) Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer 101:124-131